The Decoder · 2026/10/21 16:32:54
OpenAI 收购 Orchestra Bio 加速构建药物研发智能体
OpenAI 宣布收购初创公司 Orchestra Bio，并将其整合进生命科学平台 Rosalind。此次收购旨在打造能连接科学发现与临床试验的 AI 智能体，通过自动化追踪试验进度和预警风险，解决制药行业因系统孤岛导致的效率低下问题，从而缩短新药上市周期。
报道全文原始报道全文
OpenAI is making a bigger bet on pharmaceuticals. The company acquired Orchestra Bio, a startup that helps pharma teams coordinate drug development. Orchestra will be folded into Rosalind, OpenAI's AI platform for life sciences. GPT-Rosalind helps researchers analyze biological and chemical questions, while Rosalind Workbench connects those capabilities with scientific data and tools.
The combined effort aims to build AI agents that link scientific findings with clinical trials, decisions, and next steps to get new drugs to patients faster. Developing a drug in the US takes ten to 15 years on average. Beyond the scientific hurdles, siloed systems and the constant back-and-forth between internal teams and outside partners slow things down.
Orchestra's agents are designed to take work off teams' plates by tracking trials, flagging affected timelines when something goes wrong like a failed production batch, and surfacing options for what to do next. That could free scientists to focus on decisions and the actual research. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. Financial terms of the deal weren't disclosed.